Emerphed - (50 mg/10 mL ; Injection)

Generic Name	Ephedrine sulfate	Innovator	Nexus Pharma
Dosage	50 mg/10 mL ; Injection	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	EMERPHED is an alpha- and beta- adrenergic agonist and a norepinephrine releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*******	*** / *********	*** **, ****	*******	****	*** ****** *** ****
********	** / **	*** **, ****	*******	****	*** ****** *** ****
***** ******	** / **	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events